

International Headache Congress 2021:

International Headache Society/European Headache Federation

Meeting dates: September 8-12, 2021

Meeting location: Berlin, Germany

Abstract submission deadline: Tuesday, March 23, 11:59PM CET/**6:59PM EDT**

SUMMARY OF SOCIETY'S GUIDELINES

https://www.headache-congress.org/fileadmin/congress/media/ihs-ehf2021/pdf/IHC2021_Abstract_submission_guidelines.pdf

Character limit: 1500 characters (approx. 250 words); includes spaces and punctuation (author affiliations and titles not included in overall count)

Current count:

Title character limit: none stated

Additional society guidelines:

- Required: Select an abstract topic from list on guidelines page (link above); Scientific Committee can recategorize if deemed necessary
- Trade names are not permitted in abstract title
- Structure as Objective, Methods, Results, Conclusion
- Encores accepted; must state this during submission
- Notifications will be e-mailed during the week starting May 4
- Late breakers accepted until July 2, 2021

AUTHORS:

Richard B Lipton^{1,2}, Dawn C Buse², Shruti Vaidya³, Alex Scott³, Alice Jacobson³, Michelle Goodreau³, WF Stewart⁴, Ani Khodavirdi⁵, Marco S Navetta⁵, Mahan Chehrena⁵, Robert Urman⁵, Karminder Gill⁵, Alice Pressman³

Affiliations

1 – Albert Einstein College of Medicine, Bronx, NY 10461

2 – Montefiore Medical Center, Bronx, NY 10467

3 – Sutter Health Center for Health Systems Research, Walnut Creek, CA 94596

4 – Medcurio Inc., Oakland, CA 94618

5 – Amgen Inc., Thousand Oaks, CA 91320

Character limit (including spaces and punctuation): 1500; current count: 1482

TITLE: Relative frequency and sub-types of constipation by migraine status in a healthcare population sample: Results of the Migraine Signature Study

ABSTRACT

Objective: To determine relative frequency and subtypes of constipation among patients with migraine (M) and non-migraine headache controls (HC) in a health system sample.

Methods: A sample of adult (≥ 18 years of age) primary care patients from a California healthcare system completed a survey which included the validated AMS/AMPP diagnostic migraine questionnaire, common comorbidities, the validated ROME IV Diagnostic Questionnaire (for constipation and subtypes), and a constipation management questionnaire. M and HC groups were identified via survey and HC status was confirmed via EHR.

Results: The overall survey response rate was 1,297/2,558 (50.7%); excluding those with missing data left 807 M and 349 HC patients. Compared with HC patients, M patients were more likely to be female (M: N=654 (81.0%) vs. HC: N=211 (60.5%)), and younger with more in age 30-44 group (M: N=291 (36.1%) vs. HC: N=80 (22.9%)). Respondents with M were more likely than HC to meet ROME IV criteria for constipation (M: N=213 (26.4%) vs. HC: N=31 (8.9%)). Subtype distributions were as follows: Functional Constipation (M=15.0% vs. HC=5.2%), Irritable Bowel Syndrome with Constipation (M=11.4% vs. HC=2.9%) and Opioid Induced Constipation (M=1.2% vs. HC=0.6%).

Conclusion: Constipation overall and by subtypes was more common in patients with migraine than in headache controls, which could be influenced by responder bias. Additional work will explore constipation management and comorbidities.

Funding Source: This work was supported by a contract funded by Amgen Inc., Thousand Oaks, CA.

Disclosures:

Richard B. Lipton, MD, serves on the editorial boards of *Neurology* and *Cephalalgia* and is a senior advisor on *Headache*. He has received research support from the National Institutes of Health. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; serves as consultant, advisory board member, or has received honoraria or research support from AbbVie, Amgen, Biohaven, Dr. Reddy's Laboratories, electroCore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from *Wolff's Headache*, 8th edition (Oxford University Press, 2009), and Informa. He holds stock options in Biohaven.

Dawn C. Buse, PhD, has received grant support and honoraria from AbbVie, Amgen, Avanir, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of *Current Pain and Headache Reports*.

Shruti Vaidya has no conflict of interest to claim.

Alex Scott has no conflict of interest to claim.

Alice Jacobson has no conflict of interest to claim.

Michelle Goodreau has no conflict of interest to claim.

Walter (Buzz) F. Stewart, PhD, MPH, has received personal compensation for serving as a consultant for Amgen and Grifols.

Ani Khodavirdi, Marco Navetta, Mahan Chehrenama, Robert Urman, and Karminder Gill are employees of, and shareholders in, Amgen Inc.

Alice Pressman has no conflict of interest to claim.